Fate Therapeutics P/S 2024

Fate Therapeutics P/S

70.03

Fate Therapeutics Dividend yield

Ticker

FATE

ISIN

US31189P1021

WKN

A1W50M

As of May 31, 2024, Fate Therapeutics's P/S ratio stood at 70.03, a 792.1% change from the 7.85 P/S ratio recorded in the previous year.

The Fate Therapeutics P/S history

Fate Therapeutics Aktienanalyse

What does Fate Therapeutics do?

Fate Therapeutics Inc is a biotechnology company specializing in the development of cell therapies. The company was founded in 2007 by four scientists who recognized the need for new therapies and treatment options. Their goal was to find new ways to promote tissue and organ regeneration and repair by harnessing the biological mechanisms within cells. Fate Therapeutics' business model is to develop and market state-of-the-art cell therapies based on human stem cells. These stem cells are typically obtained from patients' bone marrow or adipose tissue and then cultured in specialized cell cultures to prepare them for medical use. Fate Therapeutics currently offers several different products and services, including: - Cell therapies for the treatment of cancer: The company has developed a range of cell therapies aimed at boosting the immune system and mobilizing against cancer cells. These therapies are based on the method of extracting so-called T cells from the patient's blood, growing and modifying them in the lab to enhance their ability to target cancer cells. - Therapies for the treatment of genetic diseases: Fate Therapeutics has also developed cell therapies aimed at treating genetic mutations or defects. These therapies are based on the method of obtaining pluripotent stem cells (iPS cells) from the patient's blood or adipose tissue and then differentiating them into specialized cell types that can be used to repair tissue damage or correct genetic defects. - Services to support research and development: Fate Therapeutics also offers services to assist researchers in developing and testing their own cell therapies. This includes the cell cultures, devices, and assays needed to generate and analyze new cell lines. Fate Therapeutics is divided into several divisions to better manage its various business areas. These divisions include: - Research & Development: This division is responsible for conducting basic research to develop and test new cell therapies. This includes both foundational research and the clinical trials necessary to evaluate the effectiveness and safety of new therapies. - Manufacturing: This division is responsible for the large-scale production and processing of Fate Therapeutics' cell therapies. The company has multiple production facilities in the United States and internationally to ensure swift and efficient manufacturing and delivery of its therapies. - Sales & Marketing: This division is responsible for marketing and selling Fate Therapeutics' cell therapies. The company works closely with doctors, clinics, and medical facilities to ensure that therapies reach the patients who need them. Overall, Fate Therapeutics has become a global leader in the development of cell therapies. The company has made significant progress in recent years in developing new therapies and continues to work on finding innovative solutions to medical challenges. With its competent leadership and top-notch products and services, Fate Therapeutics Inc. is poised for even greater success in the future. Fate Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Fate Therapeutics's P/S Ratio

Fate Therapeutics's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Fate Therapeutics's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Fate Therapeutics's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Fate Therapeutics’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Fate Therapeutics Stock

What is the price-to-earnings ratio of Fate Therapeutics?

The price-earnings ratio of Fate Therapeutics is currently 70.03.

How has the price-earnings ratio of Fate Therapeutics changed compared to last year?

The price-to-earnings ratio of Fate Therapeutics has increased by 792.1% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Fate Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Fate Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Fate Therapeutics affect the company?

An increase in the price-earnings ratio of Fate Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Fate Therapeutics affect the company?

A decrease in the price-earnings ratio of Fate Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Fate Therapeutics?

Some factors that influence the price-earnings ratio of Fate Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Fate Therapeutics pay?

Over the past 12 months, Fate Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fate Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Fate Therapeutics?

The current dividend yield of Fate Therapeutics is .

When does Fate Therapeutics pay dividends?

Fate Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fate Therapeutics?

Fate Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Fate Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fate Therapeutics located?

Fate Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fate Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fate Therapeutics from 5/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/31/2024.

When did Fate Therapeutics pay the last dividend?

The last dividend was paid out on 5/31/2024.

What was the dividend of Fate Therapeutics in the year 2023?

In the year 2023, Fate Therapeutics distributed 0 USD as dividends.

In which currency does Fate Therapeutics pay out the dividend?

The dividends of Fate Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Fate Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Fate Therapeutics

Our stock analysis for Fate Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fate Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.